Screener / SEC EDGAR /CIK 0000856982 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

Merit Medical Systems Inc MMSI

Compare with peers Embed
SEC comment letters, last 20 years

6 reviews of MMSI's filings by SEC staff

UPLOAD and CORRESP
Reviews 6 latest letter Aug 9, 2024
Questions asked 19 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 9 UPLOAD
  2. 2. Questions in them 19 numbered comments
  3. 3. Company replies 9 CORRESP
  4. 4. Reviews closed 6 of 6 closing letter

Half the closed reviews took 33 days or less from the first letter to the closing letter.

Schedule 14A

2024-08-09 to 2024-09-05 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2024-09-05
SEC asked
Please provide a clear description of the relationship between compensation actually paid and net income, as required by Item 402(v)(5)(ii) of Regulation S-K. Please note that it is not sufficient to state that no relationship exists, even if a particular measure is not used in setting compensation.
MMSI answered
The Company undertakes to provide a clear description of the relationship between compensation actually paid and net income, as required by Regulation S-K Item 402(v)(5)(ii), in its future proxy statement disclosure.

The Staff is invited to contact the undersigned with any comments or questions it may have. We appreciate your assistance in addressing this matter.
Read in the reply

Also in this review: closing letter, 2024-09-05

Form 10-K

2024-04-10 to 2024-08-13 · 6 questions · 4 letters from the SEC, 4 from the company
Review closed 2024-08-13
Results discussion (MD&A)Non-GAAP measuresLegal and contingenciesRevenueLiquidity and cash
Notes to Consolidated Financial Statements, page 59
SEC asked (1)
We note from your disclosures in your earnings press releases that you have recognized corporate transformation and restructuring charges of $19.8 million for fiscal year 2023, $23.8 million for fiscal year 2022, and $18.7 million for fiscal year 2021, representing 16%, 27% and 31% of operating income, respectively.
Rest of the question

Please tell us why you have not provided an accounting policy for recognizing restructuring charges and the disclosures required by ASC 420-10-50-1 and SAB Topic 5:P in your footnote and MD&A disclosures. 10. Commitments and Contingencies

MMSI answered
We respectfully acknowledge the Staff’s comment. For ease of the Staff’s review, we have included the following table to summarize the costs associated with our transformation and restructuring charges (in thousands):

Year Ended December 31,

2023

2022

2021

Corporate Transformation

$

12,300

16,600

18,061

Restructuring Charges

Asset Write-downs:

Property and equipment

4,334

—

Inventories

448

Employee Termination Benefits

2,731

7,157

588

Total Restructuring

7,513

Total Corporate Transformation and Restructuring

19,813

23,757

18,649

____________________

Corporate
Rest of the answer

transformation

In our Current Report on Form 8-K filed on November 10, 2020, the Company introduced a corporate transformation initiative known as “Foundations for Growth,” with multi-year financial targets for growth and improved profitability for the three-year period ended December 31, 2023. The plan to attain these targets focused on objectives including global operations and functional and commercial optimization. The primary activities associated with this transformation program were launched to drive value creation inclusive of optimizing certain commercial processes such as product life cycle management and pricing optimization, strengthening and enhancing the operating model and organizational structure, enhancing global manufacturing and supply chain processes through network consolidation and other manufacturing initiatives. As these corporate transformation initiatives are not part of the Company’s core competencies, the Company partnered with third-party consultants to develop and execute these initiatives. These transformation costs represent third-party consulting costs associated with the discrete, strategic and operational objectives under our three-year Foundations for Growth Program. We believe these costs do not meet the definition of restructuring costs as defined under ASC 420, Exit or Disposal Obligations. Rather we believe these corporate transformation costs are representative of business process reengineering activities addressed under ASC 720-45, Other Expenses – Business and Technology Reengineering.

Corporate transformation costs represent 9.9%, 19.0%, and 29.6% of operating income for the years ended December 31, 2023, 2022, 2021 respectively. Although the Foundations for Growth program has concluded, if future investments in business transformation projects are undertaken, we will include a more robust disclosure of the initiatives in our Form 10-K under Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations and Notes to the Consolidated Financial Statements. Please refer below for our proposed clarifying disclosure in the Notes to the consolidated financial statements for these transformation costs.

Restructuring

Asset write-downs: In connection with the Company’s initiatives discussed above, transformation and restructuring charges included the write-off of certain long-lived assets as a result of our decision to no longer distribute or market certain product lines; such charges were accounted for under ASC 360, Property, Plant and Equipment. Additionally, to the extent we wrote off inventories associated with the exit of specific product lines, such charges were recorded within cost of sales and accounted for under ASC 330, Inventory. We believe these charges do not meet the definition of restructuring activities in ASC 420, Exit or Disposal Cost Obligations, as the programs to which these costs relate did not materially change the scope of the business undertaken by the Company or the manner in which the Company’s business is conducted. Asset write downs represent 3.9%, 0%, and 0% of operating income for the years ended December 31, 2023, 2022, 2021 respectively.

Employee termination benefits: For the years ended December 31, 2023, 2022 and 2021, we incurred certain employee termination benefits for employees effected by certain site consolidation and production line optimization transfers related to the Company’s transformation initiatives described above. Expenses and liabilities associated with these restructuring activities were recorded in accordance with ASC 420-10-50-1; however, as the total expense and/or the accruals outstanding at the end of any given period were not significant to our consolidated financial statements we did not incorporate the full disclosures required under this guidance. Employee termination benefits represent 2.2%, 8.2%, and 1.0% of operating income for the years ended December 31, 2023, 2022, 2021 respectively.

Proposed Disclosures

In our consideration of the disclosure of an accounting policy in accordance with ASC 235, Notes to the Financial Statements, as well as the disclosure requirements of ASC 360-10-50 and ASC 420-10-50-1, we concluded that the asset write-downs and employee termination benefits, reflected in the tables above, were not material to the financial statements taken as a whole and thus no specific accounting policy or financial statement disclosure for these amounts was provided in our 2023 Form 10-K

We believe the asset write-downs and employee termination benefit charges referenced in the proceeding paragraphs are not material to the periods presented in the consolidated financial statements included in our 2023 Form 10-K; however, we acknowledge that similar charges may be material in the future. We therefore advise the Staff that in future filings, we will disclose our accounting policy for recognizing asset write-downs and employee termination benefits with transformation and restructuring activities and any disclosures required by ASC 360-10-50-1-3 and ASC 420-10-50-1. In our next filing, we will include the underlined edits to our existing Long-Lived Asset policy and add the Restructuring policy as noted below.

Long-Lived Assets. We periodically review the carrying amount of our long-lived assets, including property and equipment, intangible assets, and right-of-use operating lease assets, for impairment. An asset is considered impaired when undiscounted estimated future cash flows are less than the carrying amount of the asset based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC 360, Property, Plant and Equipment. In the event the carrying amount of such asset is not considered recoverable, the asset is adjusted to its fair value. Fair value is generally determined based on discounted future cash flow. The Company recorded write downs of property and equipment in each of the years ended December 31, 2023, 2022 and 2021.

Restructuring. Restructuring charges consist primarily of termination benefits for employees effected by certain site consolidation and production line optimization transfers related to the company’s transformation initiatives. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with ASC 420, Exit or Disposal Cost Obligations. Severance costs accounted for under ASC 420 are recognized when management with the proper level of authority commits to a restructuring plan and communicates these actions to employees and other applicable criteria. We record such costs into expense over the employee’s future service period, if any. Other exit costs are accounted for under ASC 420 and are either deferred or expensed as incurred based on the nature of the expense. We recorded restructuring charges of $2.7 million, $7.2 million and $0.6 million for the years ended December 31, 2023, 2022 and 2021, respectively. These expenses are reflected within selling, general and administrative expenses within our consolidated statements of income. The restructuring reserve balance as of December 31, 2023 and 2022 was $4.1 million and $4.6 million, respectively.

In addition to these restructuring costs, the Company incurs other costs, primarily consulting fees, related to its transformation initiatives which are recorded in selling, general and administrative expenses in the Consolidated Statements of Income. These costs were $12.3 million, $16.6 million, and $18.1 million for the years ended December 31, 2023, 2022, and 2021 respectively.

Read in the reply
Litigation, page 78
SEC asked (2)
We note your disclosure that the various claims and litigation matters you are involved in could have a material adverse effect on your financial position, results of operations and cash flows. Please provide specific disclosures for these matters.
Rest of the question

Otherwise, if true then clearly state that other than as disclosed for the SEC inquiry your claims and litigation matters are not expected to materially impact your financial position, results of operations, or cash flows individually or in the aggregate. Disclosures for the amount or range of reasonably possible loss in the aggregate, or that you are unable to reasonably estimate the amount or range, should also be provided, noting that ASC 450-20-50-4 does not require the amount or range of reasonably possible loss to be estimated with precision or certainty.

MMSI answered
In the opinion of the Company’s management, based on its examination of legal proceedings, its experience to date and discussions with external legal counsel, other than the SEC inquiry referenced in your comment, our management does not believe the Company is currently involved in any legal proceedings which, individually or in the aggregate, are expected to materially impact the Company’s financial position, results of operations or cash flows.
Rest of the answer

Footnote 10 of the Condensed Notes to Consolidated Financial Statements presented in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the U.S. Securities and Exchange Commission on April 30, 2024, contains the following disclosure:

“In management's opinion, based on its examination of these matters, its experience to date and discussion with counsel, other than the SEC Inquiry, we are not currently involved in any legal proceedings which, individually or in the aggregate, could have a material adverse effect on our financial position, results of operations or cash flows. Our management regularly assesses the risks of legal proceedings in which we are involved, and management’s view of these matters may change in the future.”

The same Footnote 10 also contains disclosure that, unless included in the Company’s legal accrual, the Company is unable to estimate a reasonably possible loss or range of loss associated with any individual material legal proceeding.

Read in the reply
Exhibit 99.1
SEC asked (3)
We note your adjustments for corporate transformation and restructuring for your non- GAAP performance measures. Please provide us with an explanation of what specifically each of these adjustments represent and quantify the components for each period presented. Confirm to us that you will provide a more detailed discussion of these adjustments along with quantifying the components for each period presented.
Rest of the question

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

MMSI answered
Please refer to our response regarding Comment 1 for a summary of the components and an explanation of the adjustments captured in our corporate transformation and restructuring charges presented in our non-GAAP performance measures.

The Foundations for Growth Program is the first whole-business transformation project the Company has undertaken. The program has been discussed with our investors in our earnings calls throughout the duration of the program.
Rest of the answer

We believe including these costs in our non-GAAP adjustments provides important indicators of our operations and provide a baseline for analyzing trends in our underlying business. The Company uses non-GAAP financial measures for reviewing our operating results and analyzing potential future business trends.

We advise the Staff that in future filings of our earnings press releases filed as exhibits to Current Reports on Form 8-K we will include additional disclosure regarding the nature and amount of the costs included within our corporate transformation and restructuring costs. In our next filing, we will include the underlined edits to the disclosures within our GAAP Net Income to Non-GAAP Net Income reconciliation tables:

Year Ended

December 31, 2023

Pre-Tax

Tax Impact

After-Tax

Per Share Impact

GAAP net income

112,089

(17,678)

94,411

1.62

Non-GAAP adjustments:

Cost of Sales

Amortization of intangibles

47,795

(11,492)

36,303

0.62

Corporate restructuring (a)

(108)

340

0.01

Inventory mark-up related to acquisitions

2,069

(497)

1,572

0.03

Operating Expenses

Contingent consideration expense

1,704

(47)

1,657

Impairment charges

270

0.00

8,293

(1,998)

6,295

0.11

Performance-based share-based compensation (b)

8,526

(1,121)

7,405

0.13

Corporate transformation and restructuring (c)

19,365

(4,646)

14,719

0.25

Acquisition-related

5,286

(1,269)

4,017

0.07

Medical Device Regulation expenses (d)

11,822

(2,838)

8,984

0.15

Other (e)

(1,268)

304

(964)

(0.02)

Other (Income) Expense

Amortization of long-term debt issuance costs

1,639

(393)

1,246

0.02

Gain on disposal of business unit

(431)

(0.01)

Non-GAAP net income

217,607

(41,783)

175,824

3.01

Diluted shares

58,356

December 31, 2022

82,629

(8,113)

74,516

1.29

42,154

(10,335)

31,819

0.55

4,611

4,625

0.08

2,219

(318)

1,901

6,300

(1,558)

4,742

5,506

(546)

4,960

0.09

(5,516)

18,241

0.32

2,114

(517)

1,597

12,933

(3,166)

9,767

0.17

7,966

(1,893)

6,073

604

(148)

456

Loss on disposal of business unit

1,407

(29)

1,378

Tax expense related to restructuring (f)

(4,324)

(0.07)

192,200

(36,449)

155,751

2.70

57,671

(a) Represents corporate restructuring charges reflected within cost of sales including the write-off of inventory related to the divestiture or exit of certain businesses or product lines.

(b) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.

(c) Includes consulting expenses of $12.3 million and $16.6 million for the years ended December 31, 2023 and 2022, respectively, related to transformation costs under our Foundations for Growth Program; includes employee termination benefits associated with restructuring activities related to corporate initiatives of $2.7 million and $7.2 million for the years ended December 31, 2023 and 2022, respectively; and in 2023, includes $4.3 million for the write-off of other long-term assets associated with the divestiture or exit of certain businesses or product lines. As of December 31, 2023, we completed the final year of our Foundations for Growth Program.

(d) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation (“MDR”).

(e) The 2023 periods include insurance reimbursement of approximately $(3.0) million for costs incurred in responding to an inquiry by the U.S. Department of Justice (the “DOJ”) which was settled in 2020, costs to comply with Merit’s corporate integrity agreement with the DOJ and acquired in-process research and development charges of $1.6 million. The 2022 periods include costs to comply with Merit’s corporate integrity agreement with the DOJ, acquired in-process research and development charges of $6.7 million, and legal costs associated with a shareholder derivative proceeding.

(f) Represents an adjustment to our deferred withholding tax liability on unremitted foreign earnings as a result of the restructuring of certain international subsidiaries in 2022.

The Staff is invited to contact the undersigned with any comments or questions it may have. We would appreciate your prompt advice as to whether the Staff has any further comments.

Read in the reply
In its next report

First report after the company's reply of May 8, 2024: 10-Q filed Aug 1, 2024 ↗, against the 10-Q filed Oct 26, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1
SEC asked
We note your responses to comments 1 and 3. Please further explain to us the specific nature of the consulting costs incurred for the corporate transformation initiative for each of the years presented addressing why these costs are not related to your operations, revenue generating activities and business strategy and thus represent normal, recurring operating expenses.
Rest of the question

In this regard, we note your statement that the purpose of the initiative is to drive value creation inclusive of optimizing certain commercial processes such as product life cycle management and pricing optimization, strengthening and enhancing the operating model and organizational structure, enhancing global manufacturing and supply chain processes through network consolidation and other manufacturing initiatives along with your statement that these costs do not represent restructuring activities. We further note your disclosure in your Form 10-Q for the first quarter of fiscal year 2024 that on February 28, 2024, you introduced your “Continued Growth Initiatives” Program and related financial targets for the three-year period ending December 31, 2026, for which you recognized consulting costs of $1 million. Refer to Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations for guidance.

MMSI answered
We respectfully acknowledge the Staff’s comment and the concern expressed under Question 100.01 of the Compliance & Disclosure Interpretations on Non-GAAP Financial Measures that presenting non-GAAP performance measures that exclude normal, recurring, cash operating expenses necessary for the operation of a registrant’s business could be misleading.
Rest of the answer

However, we believe that the relevant consulting fees reported under our corporate transformation and restructuring costs relate to discrete strategic initiatives under our Foundations for Growth (“FFG”) Program and represent appropriate adjustments to our non-GAAP measures because the costs relate to expenses which are extraordinary, unusual and non-recurring. We would like to provide the following clarifications and additional information for the Staff’s consideration.

The Company utilized the FFG Program as a vehicle to enable the Company to think holistically and comprehensively across the business. The FFG Program was the first whole-business transformation project the Company has undertaken with the input of external consultants to provide expertise and strategic guidance to the Company. The Company relied on the consultants for certain capabilities that the Company did not maintain internally. The external consultants represented temporary support teams to develop foundational processes and tool pilots during our three-year FFG Program. These transformational programs included driving implementation of network consolidation, onboarding and standing up global strategic procurement and product pricing teams through organizational realignment and integrating sales and operations planning and control tower models, as well as other programs as discussed in our letter dated May 8, 2024, to optimize our commercial and manufacturing processes. The adjustments to our non-GAAP financial measures represent only the external consulting costs we believe to be incremental and not normal, recurring, cash operating expenses necessary to operate the business.

The performance period related to the FFG Program ended on December 31, 2023. The $1 million of consulting fees reflected in our non-GAAP reconciliation for the three-month period ended March 31, 2024 represents the final costs associated with the close out of the initiatives commenced under our FFG Program.

In our press release filed as an exhibit to our Current Report on Form 8-K filed on February 28, 2024 the Company introduced our Continued Growth Initiatives (“CGI”) Program where we released the Company’s new multi-year financial targets. We believe the FFG Program established a foundation which positions the Company to achieve the financial targets under the CGI Program. It is now incumbent on our executive leaders and other employees to execute on the framework built into our foundational capabilities without reliance upon incremental third-party consultants. The FFG Program was the first step before implementation began under the CGI Program and is inherently distinct. As noted below, we have adjusted our non-GAAP measures only for the FFG Program and do not expect to make any non-GAAP adjustments for the CGI Program.

We believe the consulting costs incurred through the FFG Program represent an extraordinary, non-recurring investment in our global operations and functional and commercial optimization rather than expenses necessary to operate our business. Including these consulting costs as non-GAAP adjustments provides valuable insight for evaluating the underlying substantive fluctuations in our business and is consistent with how we evaluate the business internally and discuss the business with investors externally. Furthermore, these adjustments provide investors perspective into our business on a go-forward basis and provide better comparability to future periods in which the Company does not expect to incur similar costs. For clarity, this is consistent with the fiscal year 2024 guidance provided to our investors during our earnings call on February 28, 2024, which does not include adjustments for consulting costs outside the FFG Program. Accordingly, we believe the prior-period adjustments for the consulting fees incurred through the FFG Program presented in our non-GAAP measures will provide a consistent reflection of our underlying performance year-over-year. As noted above, the FFG Program was a unique, one-time optimization initiative that led and is expected to lead to other more detailed activities that will be recurring in nature. Based on this, we made non-GAAP adjustments related to the FFG Program, but we do not expect to adjust any costs related to the CGI Program since we view those costs as recurring in nature based on the analysis performed per Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.

We respectfully advise the Staff that in future filings beginning with our press release to be filed as an exhibit to our Current Report on Form 8-K with respect to the three-month period ending June 30, 2024, we intend to revise our disclosures on an on-going basis to include more detail regarding any consulting fees for which adjustment is made in our presentation of non-GAAP measure reconciliations (only as it relates to the FFG Program). As an example of how we plan to address the Staff’s comment in future filings and for illustrative purposes only, we have revised the disclosure (specifically footnote b) regarding corporate transformation and restructuring costs (only as it relates to the FFG Program) in the non-GAAP reconciliation tables of our press release filed as an exhibit to our Current Report on Form 8-K with respect to the three-month periods ended March 31, 2024 and 2023 as shown in the underlined text below.

Three Months Ended

March 31, 2024

Pre-Tax

Tax Impact

After-Tax

Per Share Impact

GAAP net income

$

34,348

(6,108)

28,240

0.48

Non-GAAP adjustments:

Cost of Sales

Amortization of intangibles

12,805

(3,028)

9,777

0.17

Operating Expenses

Contingent consideration benefit

(117)

(70)

(0.00)

1,764

(417)

1,347

0.02

Performance-based share-based compensation (a)

2,128

(294)

1,834

0.03

Corporate transformation and restructuring (b)

1,000

(236)

764

0.01

Acquisition-related

(9)

0.00

Medical Device Regulation expenses (c)

2,207

(521)

1,686

Other (d)

122

(30)

Other (Income) Expense

Amortization of long-term debt issuance costs

1,477

(348)

1,129

Non-GAAP net income

55,772

(10,944)

44,828

0.77

Diluted shares

58,567

March 31, 2023

25,500

(4,797)

20,703

0.36

10,616

(2,553)

8,063

0.14

Contingent consideration expense

521

(45)

476

1,665

(402)

1,263

1,287

(87)

1,200

3,546

(851)

2,695

0.05

255

(61)

194

3,658

(878)

2,780

(8)

151

(36)

115

47,233

(9,718)

37,515

0.64

58,183

Note: Certain per-share impacts may not sum to totals due to rounding.

(a) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.

(b) Includes non-recurring consulting expenses that are not part of our ongoing operations and were incurred to execute discrete transformation projects under our Foundations for Growth (“FFG”) Program. The three-month period ended March 31, 2024 includes $1.0 million for final costs associated with the close out of the initiatives commenced under our FFG program. The three-month period ended March 31, 2023 includes non-recurring consulting expenses of $1.9 million associated with our FFG Program to implement artificial intelligence (“AI”) powered tools to optimize our commercial processes and manufacturing initiatives to drive network consolidation. The 2023 period also includes restructuring costs of $1.6 million associated with employee termination benefits related to corporate initiatives.

(c) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation (“MDR”).

(d) Represents costs to comply with Merit’s corporate integrity agreement with the U.S. Department of Justice (the “DOJ”.

Read in the reply
In its next report

First report after the company's reply of May 24, 2024: 10-Q filed Aug 1, 2024 ↗, against the 10-Q filed Oct 26, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1
SEC asked
We note your response to our comment letter. Please provide us with a more detailed, specific description about the nature of the activities performed by the consultants who provided services related to your Foundations for Growth Program.
Rest of the question

As part of your detailed description of the activities performed by the consultants, address why expenses incurred to optimize your commercial and manufacturing processes are not related to your operations and revenue generating activities. In addition, explain why your use of consultants for certain capabilities that you did not maintain internally supports the corporate transformation and restructuring adjustments to your non-GAAP performance measures. In this regard, Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations states, in part, "[w]hen evaluating what is a normal, operating expense, the staff considers the nature and effect of the non-GAAP adjustment and how it relates to the company’s operations, revenue generating activities, business strategy, industry and regulatory environment." Please contact Tracey Houser at 202-551-3736 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Sincerely,

MMSI answered
We respectfully acknowledge the Staff’s comment and request for a more detailed, specific description about the nature of the activities and services performed by the consultants related to the Foundations for Growth Program (the “FFG Program”).

Description of FFG Program:

As discussed in our letter dated May 24, 2024, the FFG Program was a one-time, unique whole-business transformation project which involved, in part, the engagement of external consultants to provide expertise and strategic guidance to the Company.

Prior to the initiation of the FFG Program, the founder-led Company had
Rest of the answer

undergone a period of top-line expansion driven by a series of strategic acquisitions and a strong pipeline of organic growth through product launches and market share gains. With this expansion, the Company had reached a size and scope that prompted management to seek strategic input from external consultants to review the Company’s operating model and structure and to develop recommendations for improving operating efficiency commensurate with the sales growth. Given the unique nature of this undertaking, the Company’s management engaged on a temporary basis external consultants specialized in advising on such transformative projects. The external consultants completed a foundational business analysis and provided recommendations to drive value creation, including recommendations relating to product life cycle management, pricing mechanisms, strengthening and enhancing the organizational structure, enhancing global manufacturing and supply chain processes through network consolidation, and other manufacturing initiatives.

The following paragraphs summarize the activities that comprised the FFG Program:

● Network consolidation. This activity focused on network consolidation and line transfers of which external consultants assessed the feasibility and timing of transferring product lines across key manufacturing plants, including reviewing scenarios for potential savings and risks, business case development, project tracking, establishing regulatory-compliant timelines, and validating capacity expansion needs. These resulted in recommendations for management to consider going forward.

● Manufacturing excellence. The external consultants were engaged to improve the manufacturing process by providing guidance in the design and overhaul of the Company’s lifecycle management; design and optimization functionalities from production to supply chain; launch of a comprehensive productivity and quality program; design of dashboards to track productivity patterns and machine effectiveness; determination of requirements and design for a new supply chain management platform, and optimization of the Company’s freight and distribution network to enhance visibility about distribution costs.

● Procurement and commercial business workstream improvements. The recommendations of the consultants aimed at enhancing savings delivery. The external consultants were engaged to provide guidance in the design and delivery of a new global procurement organization and governance structure, development of a management system of direct procurement spend via advanced categorization at the product level, and in the creation of a supplier evaluation process. The consultants also provided input in the creation of a central pricing team, establishment of automated pricing dashboards and market intelligence to create enhanced visibility in pricing trends, development of compensation structure benchmarks across key competitors, and design of a new infrastructure to allow leadership to track performance.

The fees paid to the external consultants in connection with the FFG Program represented a one-time, strategic investment to analyze the Company’s business and recommend changes to foundational processes for management consideration. While the Company’s non-GAAP performance measures for the relevant periods were adjusted to exclude the extraordinary costs of engaging these external consultants, no costs associated with the implementation and ongoing operation of such strategy changes were included as adjustments in our non-GAAP measures.

The FFG Program spanned three years and ended on December 31, 2023. The final costs associated with the program were reflected in the Company’s non-GAAP reconciliation for the three-month period ended March 31, 2024. The FFG Program is complete and there will be no further costs in connection with the program.

The Company has not undertaken other high-level strategic programs similar to the FFG Program in the past and does not have plans to undertake a similar program in the future. While the Company has announced its Continued Growth Initiatives Program (the “CGI Program”) in its Current Report on Form 8-K filed on February 28, 2024, to provide investors with additional information regarding the Company’s plans and projected financial targets over the next three-year period. The CGI Program does not include the extensive engagement of external consultants to conduct a unique, whole-business analysis and transformation. To clarify, the Company has never adjusted, and does not plan in the future to adjust, its non-GAAP measures for any costs associated with the CGI Program implementation. Such costs are expected to be treated as normal operating costs.

Reasons why FFG consulting costs are not expenses necessary to operate our business:

Costs associated with the FFG Program were one-time transformative and strategic business consulting costs:

As noted above, consulting costs under the FFG Program represented unique one-time costs related to an entire business-wide transformation project the Company undertook by hiring external consultants to provide expertise and strategic guidance to maintain revenue growth, improve operating margins, and reinvigorate the organization. The strategic transformation plan spanned three years and resulted in recommendations to improve business performance. The adjustments to the Company’s non-GAAP financial measures represented only the external consulting costs we believe to be strategic and incremental to build the foundation necessary for future growth and not the normal, recurring, cash operating expenses required to operate our business. Internal operational costs were specifically not adjusted within the Company’s non-GAAP measures.

Costs associated with the FFG Program are already complete and updating old earnings guidance could be confusing to investors and analysts:

The FFG Program was introduced on our Current Report on Form 8-K filed on November 10, 2020 and the performance period ended on December 31, 2023 with the final costs associated with the program reflected in our non-GAAP reconciliation for the three-month period ended March 31, 2024. We respectfully submit that, because the FFG Program is complete and there will be no further costs associated with the program, retrospectively eliminating this adjustment for prior periods would have limited value to investors and could be potentially confusing in the context of earnings guidance that is forward-looking from a future periods’ perspective.

Only incremental external transformation costs associated with the FFG Program were adjusted and implementation and related operating costs were not adjusted:

As discussed in the “Description of FFG Program” section above, external consulting costs related to the FFG Program involved many recommendations for the Company to consider. No costs associated with the implementation and ongoing operation of such strategy changes were included as adjustments in our non-GAAP measures. To clarify, the Company strategically limited the types of costs adjusted for non-GAAP purposes to include only the external consulting costs instead of adjusting for all types of transformation costs.

Based on the discussion above, we believe the consulting costs incurred through the FFG Program as part of our Corporate Transformation and Restructuring adjustment in the calculation of our non-GAAP measures, represented a one-time investment related to strategizing our global operations rather than expenses necessary to operate our business.

Read in the reply
In its next report

First report after the company's reply of Jul 12, 2024: 10-Q filed Aug 1, 2024 ↗, against the 10-Q filed Oct 26, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

SEC asked
We note your response to our comment letter. Based on the information provided for the Foundations for Growth Program costs captured in the corporate transformation and restructuring non-GAAP adjustment, these costs appear to have been incurred in the normal course of your operations.
Rest of the question

With reference to Question 100.01 of the Compliance and Disclosure Interpretations for Non-GAAP Financial Measures, please confirm that you will no longer exclude the corporate transformation costs from your non-GAAP measures.

MMSI answered
Commencing with our Current Report on Form 8-K to be filed later today, financial information presented in earnings releases and other presentation materials which include non-GAAP financial measures will not exclude consulting costs associated with our Foundations for Growth Program from our non-GAAP measures. Prior period presentations of such information will be recast to conform with the current year presentation.
Read in the reply

Also in this review: closing letter, 2024-08-13

Schedule 14A

2023-11-09 to 2023-12-19 · 4 questions · 1 letter from the SEC, 1 from the company
Review closed 2023-12-19
Executive pay
Definitive Proxy Statement on Schedule 14A filed April 4, 2023 · Pay Versus Performance, page 68
SEC asked (1)
Please ensure that the amounts included in the pay versus performance table with respect to your total shareholder return and your peer group total shareholder return are presented as dollar figures and not as percentages. Refer to Regulation S-K Item 402(v)(2)(iv).
MMSI answered
The Company will ensure that the amounts included in the pay versus performance table with respect to total shareholder return and peer group total shareholder return are presented as dollar figures and not as percentages in its future proxy statement disclosures.
Read in the reply
Definitive Proxy Statement on Schedule 14A filed April 4, 2023 · Pay Versus Performance, page 68
SEC asked (2)
It appears that you have not provided the relationship disclosures required by Regulation S-K Item 402(v)(5). Please provide this required disclosure in its entirety. Although you may provide this information graphically, narratively, or a combination of the two, this disclosure must be separate from the pay versus performance table required by Regulation S-K Item 402(v)(1) and must provide a clear description of
Rest of the question

each separate relationship indicated in Regulation S-K Item 402(v)(5)(i)-(iv). Please note, it is not sufficient to state that no relationship exists, even if a particular measure is not used in setting compensation.

MMSI answered
The Company will ensure that the relationship disclosures required by Regulation S-K Item 402(v)(b) are included in its future proxy statement disclosures. The Company will also ensure that these disclosures are separate from the pay versus performance table required by Regulation S-K Item 402(v)(1) and include a clear description of each separate relationship indicated in Regulation S-K Item 402(v)(5)(i)-(iv).
Read in the reply
Definitive Proxy Statement on Schedule 14A filed April 4, 2023 · Pay Versus Performance, page 68
SEC asked (3)
Please provide a Tabular List that includes your Company-Selected Measure and at least three, and up to seven, financial performance measures, which represent the most important financial performance measures that you use to link compensation actually paid to your named executive officers, for the most recently completed fiscal year, to company performance. Refer to Regulation S-K Item 402(v)(6).
MMSI answered
The Company will ensure that its future proxy statement disclosures include a Tabular List that includes our Company-Selected Measure and at least three, and up to seven, financial performance measures, which represent the most important financial performance measures that we use to link compensation actually paid to our named executive officers, for the most recently completed fiscal year, to company performance.
Read in the reply
Definitive Proxy Statement on Schedule 14A filed April 4, 2023 · Pay Versus Performance, page 68
SEC asked (4)
We note your disclosure that your peer group total shareholder return is based on "NASDAQ Stocks (SIC 3840-3849 US Companies Surgical, Medical, and Dental Instruments and Supplies)." It is unclear whether such peer group is a published industry or line-of-business index. If it is not, please ensure that you disclose in a footnote the identity of the issuers composing the group.
Rest of the question

Refer to Regulation S-K Item 402(v)(2)(iv).

MMSI answered
The Company will ensure that its peer group total shareholder return disclosure in future proxy statements clearly indicates whether it has been derived from a published industry or line-of-business index.

The Staff is invited to contact the undersigned with any comments or questions it may have. We would appreciate your prompt advice as to whether the Staff has any further comments.
Read in the reply

Also in this review: closing letter, 2023-12-19

Form 10-K for the Fiscal Year Ended December 31, 2017

2018-03-29 to 2018-04-20 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2018-04-20
Russia and UkraineRevenue
General
SEC asked (1)
In your letter to us dated August 20, 2015, you discussed contacts with Syria and Sudan. As you know, Syria and Sudan are designated by the State Department as state sponsors of terrorism and are subject to U.S. economic sanctions and/or export controls. You do not provide disclosure about Syria or Sudan in your Form 10-K.
Rest of the question

Please describe to us the nature and extent of any contacts with Syria and Sudan since your 2015 letter, whether through subsidiaries, distributors or affiliates. In this regard, we note that you recently acquired certain assets from Becton, Dickinson & Co. In a letter to us dated February 17, 2017, Becton, Dickinson & Co. discussed contacts with Syria and Sudan. Please include information about any contacts with Syria and Sudan since that date with respect to the assets you purchased. Tell us whether any contacts involve the governments of Syria or Sudan, or entities controlled by their governments.

MMSI answered
Syria:

Similar to the situation we discussed in our August 20, 2015 letter, pursuant to the Export Licenses referenced below, Merit sells a small quantity of medical devices to a single independent distributor located in Syria. It is our understanding that the Syrian distributor then resells our products to “approved end users” (as defined in the Export Licenses), consisting of hospitals and clinics located in Syria.
Rest of the answer

Except as contemplated by a marketing and

Cecilia Blye

United States Securities and Exchange Commission distribution agreement we have executed with our Syrian distributor (the “Distributor Agreement”), neither Merit nor any of its subsidiaries has any direct or indirect contacts with, or sales into, Syria.

Our relationship with the Syrian distributor is subject to, and governed by, export licenses (the “Export Licenses”) issued by the U.S. Department of Commerce, Bureau of Industry and Security (the “BIS”). We currently hold two separate Export Licenses with respect to sales into Syria. Each Export License specifies the authorized distributor, the authorized products and pricing and the approved customers to whom our Syrian distributor is permitted to resell such products. At present, we intend to continue selling authorized products to the Syrian distributor for resale in Syria pursuant to the terms of existing and future Export Licenses and the Distributor Agreement. We do not have a relationship or arrangement with the government of Syria or entities controlled by its government.

Sudan:

As was the case at the time of our August 20, 2015 letter, neither Merit nor any of its subsidiaries has any contacts or commercial relationships, direct or indirect, in Sudan or any direct or indirect relationship or arrangement with the government of Sudan or entities controlled by the government of Sudan.

Products Acquired from Becton, Dickinson & Co.:

With respect to our recent acquisition of certain medical device products (the “BD Products”) from Becton, Dickinson & Co. (“BD”), we did not acquire any distribution agreements, contracts or export licenses issued by BIS which obligate or allow us to sell the BD Products in Syria or Sudan. Although we do not currently sell any BD Products into Syria or Sudan, it is possible that, at some point in the future, we may consider selling one or more BD Products into Syria through a distributor. If, in the future, we elect to sell any BD Products into Syria, we would not expect any such sales to be material to our security holders, whether viewed qualitatively or quantitatively, and any such sales would be conducted pursuant to valid Export Licenses.

Read in the reply
General
SEC asked (2)
Please also discuss the materiality of any contacts, in quantitative terms and in terms of qualitative factors that a reasonable investor would deem important in making an investment decision. Tell us the approximate dollar amounts of any revenues, assets and liabilities associated with Sudan and Syria for the last three fiscal years and the subsequent interim period.
Rest of the question

Address the potential impact of the investor sentiment evidenced by divestment and similar initiatives that have been directed toward companies with operations associated with U.S.-designated state sponsors of terrorism.

MMSI answered
As discussed in our August 20, 2015 letter, we do not believe our sales to, and relationship with, our Syrian distributor-which constitute our sole contacts with Syria-is material to our security holders, whether viewed qualitatively or quantitatively. Our assessment of the materiality of our contacts with Syria is based upon the following factors:

Quantitative Analysis:

The aggregate net sales revenue we generated from sales of our products into Syria in the years ended December 31, 2015, 2016 and 2017 and in the three months ended March 31, 2018 were approximately $139,372, $116,862,
Rest of the answer

$75,922, and $79,679, respectively, representing less than 0.04% of our total net sales generated in each period. Additionally, we do not maintain any facilities or other assets in Syria, do not have any liabilities attributable to sales of our products in Syria, and do not conduct any operations or maintain any employees in Syria.

For these reasons, we do not believe that our contacts with Syria-which are limited to the small quantity of products sold to our Syrian distributor, as discussed above-are significant, viewed from a quantitative perspective.

Qualitative Analysis:

Our limited sales into Syria are governed by the Export Licenses, which are overseen by BIS. Our net sales generated in Syria from such products constituted a very small amount of our total net sales for the periods referenced above. Additionally, our products are used in the treatment of disease and the alleviation of medical conditions, which we believe further mitigate investor concerns regarding our activities associated with Syria.

For these reasons, we do not believe that our contacts with Syria-which are limited to the small quantity of products sold to our Syrian distributor-are significant, viewed from a qualitative perspective.

Investor Sentiment:

We are aware some investors may be sensitive to sales in sanctioned countries, and that state and municipal governments and other investors have proposed or adopted divestment or similar initiatives regarding investment in companies that do business with U.S.-designated state sponsors of terrorism. In this regard, we have not experienced any significant adverse reaction by investors to our activities in Syria and, given the relatively small amount of these sales and the medical purposes for which our products are used, we do not currently anticipate that our sales in Syria will result in any adverse impact on investor sentiment in the future.

As noted above, neither Merit nor any of its subsidiaries has any contacts or commercial relationships, direct or indirect, in Sudan. Specifically, we do not (a) sell any products into Sudan, (b) maintain any facilities or other assets in Sudan, (c) have any liabilities attributable to sales in Sudan or (d) conduct any operations or maintain any employees in Sudan.

Consequently, we do not believe our security holders are subject to investment risk attributable to Sudan.

If you would like to discuss any issues presented by the responses contained in this Letter, feel free to contact me at (801) 208-4236 or our outside legal counsel, Bryan Allen, at (801) 257-7963.

Read in the reply

Also in this review: closing letter, 2018-04-20

Form 10-K for the Fiscal Year Ended December 31, 2016

2017-07-07 to 2017-08-09 · 4 questions · 1 letter from the SEC, 1 from the company
Review closed 2017-08-09
Income taxesNon-GAAP measuresResults discussion (MD&A)
Management’s Discussion and Analysis of Financial Condition and Results of Operations · Effective Tax Rate, page 45
SEC asked (1)
Revise this section in future filings to explain in greater depth the impact of tax credits and earnings from non-U.S. lower taxed jurisdictions on your effective tax rate. Discuss the primary taxing jurisdictions where your foreign earnings are derived, the location of tax credits and tax holidays, and the relevant statutory rates in those jurisdictions.
Rest of the question

Discuss the expiration of, and any uncertainties relating to, the income tax rates or benefits you currently receive in those jurisdictions. Refer to Item 303(a)(3) of Regulation S-K.

MMSI answered
The Company has reviewed your comment and will revise its discussion of the effective tax rate and related disclosure in future filings to conform to your comment.
Read in the reply
In its next report

First report after the company's reply of Jul 28, 2017: 10-Q filed Aug 7, 2017 ↗, against the 10-Q filed May 10, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 8. Financial Statements and Supplementary Data · Note 5. Income Taxes, page 71
SEC asked (2)
You state that you did not provide for U.S. taxes on earnings of certain foreign subsidiaries held for permanent reinvestment outside the United States. Revise this note in future filings to disclose the cumulative amount of the undistributed earnings related to the unrecognized deferred tax liability for this temporary difference, as required by ASC 740-30-50.b.
MMSI answered
The Company has reviewed your comment and will revise its note in future filings to conform to your comment.
Read in the reply
In its next report

First report after the company's reply of Jul 28, 2017: 10-Q filed Aug 7, 2017 ↗, against the 10-Q filed May 10, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1
SEC asked (3)
We note that on pages 1, 2 and 6 of your earnings release you discuss “non-GAAP EPS” and “non-GAAP net income” but in the tables you reconcile to measures titled “Adjusted net income (per share).” To eliminate possible investor confusion, please revise future filings to consistently use the same titles for the non-GAAP measures presented in both the narrative and the tables.
MMSI answered
The Company has reviewed your comment and will revise its disclosure in future filings to conform to your comment.
Read in the reply
In its next report

First report after the company's reply of Jul 28, 2017: 10-Q filed Aug 7, 2017 ↗, against the 10-Q filed May 10, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1
SEC asked (4)
Revise your presentation of non-GAAP measures in future filings to provide the reconciliation of Non-GAAP Gross Margin to the most directly comparable GAAP measure as required by Item 10(e)(1)(i)(B) of Regulation S-K.
MMSI answered
The Company has reviewed your comment and will revise its future filings to conform to your comment.

* * * *

Please let me know of any additional requests for information or any follow up on these matters. Please do not hesitate to call me at (801) 208-4236.
Read in the reply
In its next report

First report after the company's reply of Jul 28, 2017: 10-Q filed Aug 7, 2017 ↗, against the 10-Q filed May 10, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-08-09

Form 10-K for the Fiscal Year Ended December 31, 2014

2015-08-06 to 2015-09-03 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2015-09-03
Russia and UkraineRevenue
General
SEC asked (1)
We note that a transcript of your fourth quarter 2013 earnings conference call posted on the internet in February 2014 includes a statement by your President and CEO that you had growth in Europe despite events in the Middle East, including Syria, where you sell product. You disclose in the 10-K that you distribute your products in Africa.
Rest of the question

Syria and Sudan, a country located in Africa, are designated by the State Department as state sponsors of terrorism and are subject to U.S. economic sanctions and export controls. Your Form 10-K does not include disclosure regarding those countries. Please describe to us the nature and extent of your past, current, and anticipated contacts with Syria and Sudan, whether through subsidiaries, affiliates, distributors, resellers, or other direct or indirect arrangements. You should describe any products or services you have provided, directly or indirectly into those countries, and any agreements, commercial arrangements, or other contacts with the governments of those countries or entities they control.

MMSI answered
We currently sell multiple product lines, consisting primarily of [***], in Syria through [***], who purchases our products from us in arms-length transactions and resells those products pursuant to the terms of a marketing and distribution agreement. Our relationship with [***], which has existed since approximately [***], is governed by Export Licenses issued by the U.S. Department of Commerce, Bureau of Industry and Security (the “Export Licenses”). During the periods identified in your letter, we have held [***] separate Export Licenses.
Rest of the answer

Each Export License specifies the authorized distributor and the approved end users to whom our distributer is permitted to resell our products. We have not entered into any agreements, commercial arrangements or other contracts with the government of Syria.

At present, we hope to continue selling our products in Syria pursuant to the terms of existing and future Export Licenses. While we hope our Syrian product sales will grow incrementally, we currently anticipate that our future Syrian product sales will continue in the general range of the last three fiscal years.

We do not sell any products into Sudan, and have not entered into any agreement, commercial arrangement or other contract with the government of Sudan. We do not presently anticipate selling our products into Sudan in the future.

Read in the reply
General
SEC asked (2)
Please discuss the materiality of the contacts with Syria and Sudan you describe in response to the comment above, and whether those contacts constitute a material investment risk for your security holders. You should address materiality in quantitative terms, including the approximate dollar amounts of any associated revenues, assets, and liabilities for the last three fiscal years and the subsequent interim
Rest of the question

period. Also, address materiality in terms of qualitative factors that a reasonable investor would deem important in making an investment decision, including the potential impact of corporate activities upon a company’s reputation and share value. As you know, various state and municipal governments, universities, and other investors have proposed or adopted divestment or similar initiatives regarding investment in companies that do business with U.S.-designated state sponsors of terrorism. You should address the potential impact of the investor sentiment evidenced by such actions directed toward companies that have operations associated with Syria and Sudan.

MMSI answered
We do not believe our relationship with [***] constitutes a material investment risk for our security holders. The principal reasons for that conclusion are discussed below. Because we do not sell any products into Sudan, we do not believe our security holders are subject to investment risk attributable to the activities of that country.

Our assessment of the materiality of our contacts with Syria is based upon the following factors. Our product sales into Syria are conducted through [***], pursuant to the terms of the Export Licenses.
Rest of the answer

The Export Licenses expressly define “approved end users,” consisting of hospitals and clinics, to whom [***] is permitted to resell our products. For the fiscal years ended December 31, 2012, 2013 and 2014, the aggregate net sales revenues we generated from sales of our products into Syria were approximately $[***], $[***] and $[***], respectively, representing less than [***] of our net sales for each of those years. For the six months ended June 30, 2015, the aggregate net sales we generated from sales of our products into Syria was approximately $[***], also representing less than [***] of our net sales for that period. We do not maintain any facilities or other assets in Syria, and do not have any liabilities attributable to sales of our products in Syria, other than our obligations arising pursuant to the marketing and distribution agreement we have executed with [***]. We do not conduct any operations or maintain any employees in Syria.

Because our product sales into Syria are limited to [***] and are governed by Export Licenses which are overseen by the Bureau of Industry and Security, and the net sales we generated from sales of our products into Syria for the periods identified above were less than [***] of our net sales for the periods referenced above, we do not believe the relationship with [***] poses a material investment risk to our security holders. Our determination is also based, in part, on the fact that our products are used in the treatment of disease and the alleviation of medical conditions, which we believe may mitigate investor concerns regarding activities associated with Syria.

By this letter, we also acknowledge that:

(i)

Merit is responsible for the adequacy and accuracy of the disclosure in the filing identified above;

(ii) staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing identified above; and

(iii)

Merit may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: closing letter, 2015-09-03

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Apr 12, 2018 · SEC: review completed · Merit Medical Systems, Inc. · Preliminary Proxy Statement on Schedule PRE 14A · Filed...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 25 letters filed since 2015-08-06. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MMSI/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.